KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to -$3.3 billion.

  • Astrazeneca's Cash from Financing Activities fell 38912.07% to -$3.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.5 billion, marking a year-over-year decrease of 8878.88%. This contributed to the annual value of -$7.5 billion for FY2025, which is 8878.88% down from last year.
  • Astrazeneca's Cash from Financing Activities amounted to -$3.3 billion in Q4 2025, which was down 38912.07% from -$2.1 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Cash from Financing Activities ranged from a high of $7.3 billion in Q2 2021 and a low of -$4.1 billion during Q3 2024
  • Its 5-year average for Cash from Financing Activities is -$1.0 billion, with a median of -$1.4 billion in 2022.
  • As far as peak fluctuations go, Astrazeneca's Cash from Financing Activities surged by 19985.23% in 2024, and later tumbled by 38912.07% in 2025.
  • Over the past 5 years, Astrazeneca's Cash from Financing Activities (Quarter) stood at -$1.1 billion in 2021, then fell by 23.22% to -$1.3 billion in 2022, then fell by 17.3% to -$1.5 billion in 2023, then skyrocketed by 55.83% to -$671.0 million in 2024, then plummeted by 389.12% to -$3.3 billion in 2025.
  • Its Cash from Financing Activities stands at -$3.3 billion for Q4 2025, versus -$2.1 billion for Q3 2025 and $518.0 million for Q2 2025.